Biotron's (ASX:BIT) Phase 2 trial shows positive results for HIV treatment
Biotechnology company Biotron reported preliminary results from its BIT225-010 Phase 2 trial in HIV-infected individuals.
The data indicates BIT225's unique impact on HIV, targeting the virus in reservoir cells, surpassing current antiretroviral drugs.
The 24-week trial assessed BIT225's safety, efficacy, and effect when added to standard therapy.
The trial demonstrated BIT225's ability to rapidly reduce plasma virus levels, potentially affecting viral decay and latent reservoirs.
#News #ASX #Tech #BioTech #Technology
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
